Poly(ethylene carbonate) as a surface-eroding biomaterial for in situ forming parenteral drug delivery systems: a feasibility study
Standard
Poly(ethylene carbonate) as a surface-eroding biomaterial for in situ forming parenteral drug delivery systems: a feasibility study. / Liu, Yu; Kemmer, Annette; Keim, Klaus; Curdy, Catherine; Petersen, Holger; Kissel, Thomas.
in: EUR J PHARM BIOPHARM, Jahrgang 76, Nr. 2, 10.2010, S. 222-9.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Poly(ethylene carbonate) as a surface-eroding biomaterial for in situ forming parenteral drug delivery systems: a feasibility study
AU - Liu, Yu
AU - Kemmer, Annette
AU - Keim, Klaus
AU - Curdy, Catherine
AU - Petersen, Holger
AU - Kissel, Thomas
N1 - Copyright © 2010 Elsevier B.V. All rights reserved.
PY - 2010/10
Y1 - 2010/10
N2 - To evaluate the technical feasibility of poly(ethylene carbonate), PEC, for injectable in situ forming drug delivery systems, the physical properties of PEC solutions were characterized. The solubility of PEC was investigated in different solvents, and the Hildebrand solubility parameters and Flory-Huggins interaction parameters of PEC were determined. By turbidity titration, the experimental ternary phase diagram of water-NMP/DMSO-PEC was constructed. NMP solution required more water to precipitate PEC compared to DMSO solution. The dynamic viscosity of PEC solution increased at lower temperature, higher polymer concentration and longer aging time. Differential scanning calorimetric (DSC) measurements confirmed only weak physical interactions in the system after aging, and the physical aging effect was thermo-reversible. Release of NMP from PEC formulations was twofold slower than that of DMSO at similar concentrations. The morphology of PEC depots after injection into aqueous solution was studied using scanning electron microscopy (SEM). A DMSO formulation of bovine serum albumin displayed less burst release than a NMP formulation. In summary, our investigations demonstrate that in situ depot forming systems can be obtained from PEC solutions. Moreover, a solution of PEC in DMSO would be preferred over NMP due to the reduced burst release.
AB - To evaluate the technical feasibility of poly(ethylene carbonate), PEC, for injectable in situ forming drug delivery systems, the physical properties of PEC solutions were characterized. The solubility of PEC was investigated in different solvents, and the Hildebrand solubility parameters and Flory-Huggins interaction parameters of PEC were determined. By turbidity titration, the experimental ternary phase diagram of water-NMP/DMSO-PEC was constructed. NMP solution required more water to precipitate PEC compared to DMSO solution. The dynamic viscosity of PEC solution increased at lower temperature, higher polymer concentration and longer aging time. Differential scanning calorimetric (DSC) measurements confirmed only weak physical interactions in the system after aging, and the physical aging effect was thermo-reversible. Release of NMP from PEC formulations was twofold slower than that of DMSO at similar concentrations. The morphology of PEC depots after injection into aqueous solution was studied using scanning electron microscopy (SEM). A DMSO formulation of bovine serum albumin displayed less burst release than a NMP formulation. In summary, our investigations demonstrate that in situ depot forming systems can be obtained from PEC solutions. Moreover, a solution of PEC in DMSO would be preferred over NMP due to the reduced burst release.
KW - Animals
KW - Calorimetry, Differential Scanning
KW - Cattle
KW - Delayed-Action Preparations
KW - Dimethyl Sulfoxide
KW - Drug Delivery Systems
KW - Drug Storage
KW - Feasibility Studies
KW - Microscopy, Electron, Scanning
KW - Microspheres
KW - Polyethylenes
KW - Pyrrolidinones
KW - Serum Albumin, Bovine
KW - Solubility
KW - Solvents
KW - Temperature
KW - Time Factors
KW - Viscosity
KW - Comparative Study
KW - Journal Article
U2 - 10.1016/j.ejpb.2010.07.009
DO - 10.1016/j.ejpb.2010.07.009
M3 - SCORING: Journal article
C2 - 20650316
VL - 76
SP - 222
EP - 229
JO - EUR J PHARM BIOPHARM
JF - EUR J PHARM BIOPHARM
SN - 0939-6411
IS - 2
ER -